Emergence of CTX-M-15 extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates in Bosnia and Herzegovina  by Dedeic-Ljubovic, A. et al.
Emergence of CTX-M-15 extended-spectrum b-lactamase-producing
Klebsiella pneumoniae isolates in Bosnia and Herzegovina
A. Dedeic-Ljubovic1, M. Hukic1, Y. Pfeifer2, W. Witte2, E. Padilla3, I. Lo´pez-Ramis3 and S. Albertı´3
1) Institute of Clinical Microbiology, University of Sarajevo Clinics Centre, Sarajevo, Bosnia and Herzegovina, 2) Robert Koch Institute, Wernigerode, Germany
and 3) Departamento de Biologı´a and Institut Universitari d’Investigacions en Cie`ncies de la Salut (IUNICS), Universitat de les Illes Balears (UIB), Palma de
Mallorca, Spain
Abstract
Fifty-seven nosocomial Klebsiella pneumoniae isolates producing extended-spectrum b-lactamases (ESBLs) were collected between
February 2007 and November 2007 in different wards of the Sarajevo (Bosnia-Herzegovina) reference hospital. These isolates comprise
two major epidemic pulsed-ﬁeld electrophoresis-deﬁned clones plus two minor clones. In addition to the ESBL-mediated resistance, all
strains uniformly showed resistance to ciproﬂoxacin, gentamicin and tobramycin. The b-lactamases involved in this resistance phenotype
were TEM-1, SHV-1, and CTX-M-15, as demonstrated by isoelectric focusing, PCR ampliﬁcation, and sequencing. TEM-1 and CTX-M-15
b-lactamases, as well as the aminoglycoside resistance determinants, were encoded in plasmids that could be transferred to Escherichia
coli by conjugation. In three of the infected patients with the predominant clone, cefoxitin resistance development (MICs >128 mg/L)
was documented. The analysis of the outer membrane proteins of the cefoxitin-susceptible and cefoxitin-resistant isolates revealed that
the former expressed only one of the two major porins, OmpK36, whereas in the latter, the expression of Ompk36 was altered
or abolished. This is the ﬁrst report of CTX-M-15-producing K. pneumoniae in Bosnia-Herzegovina. Furthermore, we document and
characterize for the ﬁrst time cefoxitin resistance development in CTX-M-15-producing K. pneumoniae.
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Extended-spectrum b-lactamases (ESBLs) represent a major
threat among multidrug-resistant bacterial isolates. The pro-
duction of ESBLs in Enterobacteriaceae confers resistance to
all penicillins and cephalosporins (with the exception of ceph-
amycins, in some cases), with the organisms generally
remaining susceptible only to b-lactam–b-lactamase inhibitor
combinations, such as amoxycillin–clavulanate, and the carba-
penems, which are frequently the only therapeutic options
available for treatment of hospital-acquired severe infections
caused by these microorganisms [1]. Co-resistance to non-
b-lactam antibiotics is also frequent, either by the co-transfer
of the resistance determinants in the same genetic elements
(such as aminoglycoside resistance) or simply by the
co-selection of both resistance mechanisms, as occurs with
ﬂuoroquinolones [2].
The classical ESBLs are those derived from the broad-
spectrum enzymes TEM-1, TEM-2 and SHV-1 by the acquisi-
tion of speciﬁc point mutations that expand their spectrum
of hydrolysis to oxyimino-cephalosporins and aztreonam [3].
Nevertheless, the most widespread plasmid-mediated ESBLs
nowadays are the CTX-M enzymes, which are directly
derived from the chromosomal b-lactamases of several spe-
cies of the genus Kluyvera [4]. Five different groups of CTX-
Ms, containing a total of over 80 different variants, have been
described so far, but CTX-M-2, CTX-M-3, CTX-M-14 and
CTX-M-15 are the most widespread enzymes [4].
To date, only SHV-5 b-lactamase has been reported in 14
Klebsiella pneumoniae community-isolated strains in Bosnia-
Herzegovina [5], with no record of CTX-M ESBLs in any
species. Given the scarcity of data from this country, the aim
of the present study was to characterize the ESBL-producing
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isolates of K. pneumoniae at the molecular level in the refer-
ence hospital of the capital of this country, to investigate
whether the CTX-M-type ESBLs have appeared in K. pneumo-
niae from Bosnia-Herzegovina.
Materials and Methods
Clinical strains and antibiotic susceptibility testing
The isolates included in this study comprised one from each
adult patient admitted between February and November of
2007 to the clinical centre (1762 beds, reference public
hospital from the city of Sarajevo, Bosnia and Herzegovina)
and infected with an ESBL-producing K. pneumoniae strain.
Bacterial identiﬁcation and initial susceptibility testing was
performed with the VITEK-2 system (bioMe´rieux, Hazel-
wood, MO, USA). Additionally, the MICs of several antibiot-
ics were determined by microdilution or by using Etest
strips (AB Biodisk, Solna, Sweden), following the manufac-
turer’s recommendations.
Double-disk synergy testing (DDST) for the detection of
ESBL production was performed using amoxycillin–clavula-
nate, cefotaxime, ceftazidime, cefepime and aztreonam disks
that were applied 30 and/or 20 mm apart [6]. Phenotypic
detection of AmpC was performed using the disk-based
inhibitor assay, using boronic acid or cloxacillin as an AmpC
inhibitor [7].
Molecular strain typing
The clonal relationship between the different isolates was
studied by pulsed-ﬁeld gel electrophoresis (PFGE). Agarose
plugs containing total bacterial DNA were prepared as
described elsewhere [8]. Plugs were then digested with XbaI
and loaded into a 1% Megabase agarose (Bio-Rad, La Jolla, CA,
USA) gel. DNA separation was performed in a CHEF-DRIII
apparatus (Bio-Rad) under the following conditions: 6 V/cm2
for 20 h at 14C, with initial and ﬁnal pulse times of 2 s and
35 s, respectively. The results were interpreted following the
criteria of Tenover et al. [9]. Comparison of sample proﬁles
and generation of dendrograms was carried out by hierarchical
clustering analysis using the unweighted pair group moving
average method and the Dice coefﬁcient for distance measure,
using the software PAST-Paleontological Statistics v.1.29.
Characterization of b-lactamases and their genes
The pIs of the b-lactamases were determined by isoelectric
focusing, applying the supernatants of crude sonic cell extracts
to Phast gels (Pharmacia AB, Uppsala, Sweden) with a pH gra-
dient of 3–9 in a Phast system (Pharmacia AB). b-Lactamases
with known pI values (TEM-1, TEM-2, TEM-4, TEM-3, SHV-1,
CTX-M-10 and CTX-M-1) were included as controls. Gels
were stained with 500 mg/L nitroceﬁn (Oxoid, Madrid, Spain)
to identify the bands corresponding to b-lactamases.
PCRs for genes encoding TEM, SHV and CTX-M b-lacta-
mases were performed using primers and conditions
described previously [10,11]. PCR products were sequenced
on both strands, using the BigDye terminator kit (PE-Applied
Biosystems, Barcelona, Spain) for performing the sequencing
reactions, which were analysed with the ABI Prism 3100
DNA sequencer (PE-Applied Biosystems).
Conjugation and plasmid analysis
Conjugation experiments were performed by ﬁlter mating,
using a rifampin-resistant mutant of Escherichia coli strain HB101
as the recipient at a 1 : 1 ratio. Transconjugants were selected
in Luria–Bertani agar plates containing 100 mg/L rifampin and
2 mg/L cefotaxime. Transconjugants were checked by DDST,
PCR ampliﬁcation, and sequencing of the appropriate ESBL-
encoding gene, and Etest testing of susceptibility to all b-lactams
and non-b-lactams to determine the resistance determinants
co-transferred with the ESBL. For the analysis of the plasmids,
plasmid DNA was obtained from the transconjugants using the
QIAGEN plasmid Midi kit (Qiagen, Hilden, Germany), following
the manufacturer’s instructions. Plasmids were digested with
EcoRI or BamHI, and the resulting restriction fragments were
separated by electrophoresis in a 1% agarose gel.
Isolation and analysis of outer membrane proteins (OMPs)
Isolation of OMPs was performed as previously described
[12]. Electrophoretic analysis of OMPs by SDS-PAGE was
performed with 11% acrylamide–0.35% bisacrylamide–0.1%
SDS by using Laemmli’s buffer and Coomassie blue staining.
Western blot analysis of SDS-PAGE-separated OMPs was
performed with the buffers and conditions described by
Herna´ndez-Alle´s et al. [12].
Results
In 2007, the prevalence of ESBL-producing microorganisms
at the Sarajevo clinical centre was 19.6%, K. pneumoniae
being the most prevalent species (88.8%). In fact, 68.8% of
the K. pnemoniae clinical isolates produced an ESBL. To
characterize these isolates, all nosocomial ESBL-producing
K. pneumoniae isolates infecting adult patients admitted to
the clinical centre between February and November of 2007
were collected, and one randomly selected isolate from each
patient was further characterized by PFGE.
Representative PFGE proﬁles of these isolates (n = 57)
are shown in Fig. 1. Four distinct PFGE types, designated A,
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B, C and D, were identiﬁed. The prevalent PFGE types
encountered were type A and type B, with 35 and 17
isolates, respectively. Altogether, these PFGE types repre-
sented 91.2% of the isolates.
The ﬁrst clonal ESBL-producing isolate appeared in
February, and it was a PFGE type B strain. PFGE type A and
type B strains were isolated throughout the year, reaching a
maximum in August and February, respectively. They were
isolated from urine infections (30 type A and eight type B),
blood (four type A and ﬁve type B), and wound infections
(one type A and one type B). Three PFGE type B strains
were isolated from respiratory infections. Both types were
isolated in at least seven different wards of the hospital.
All of the K. pneumoniae isolates had the same pattern of
multiresistance, showing, in addition to the ESBL-mediated
resistance to penicillins and cephalosporins, resistance to
ciproﬂoxacin, gentamicin, and tobramycin (Table 1). All
isolates with this pattern of multiresistance were uniformly
susceptible to imipenem.
In order to identify the b-lactamases present in these iso-
lates, we ampliﬁed the DNA from all ESBL-producing iso-
lates, using the speciﬁc primers described previously [10,11].
Sequencing of the PCR products conﬁrmed the presence of
TEM-1, SHV-1 and CTXM-15 in all K. pneumoniae isolates,
independently of the PFGE type exhibited. Isoelectrofocusing
conﬁrmed the presence of three b-lactamase bands with pIs
of 5.4, 7.6 and 8.6, co-focusing with TEM-1, SHV-1 and
CTXM-15, respectively.
We investigated whether the multiresistant phenotype
exhibited by these isolates was due to the transference of a
unique plasmid encoding the b-lactamases. Plasmid location
of these b-lactamases was demonstrated by conjugation
experiments. Plasmid DNA from two randomly selected iso-
lates from each PFGE type was transferred to E. coli, and
transconjugants growing on Luria–Bertani agar plates
containing 2 mg/L cefotaxime were checked by DDST,
followed by PCR ampliﬁcation and sequencing with the
speciﬁc primers.
The MICs for the E. coli transconjugants are shown in
Table 1. As can be observed, in addition to the ESBL-medi-
ated resistance pattern, aminoglycoside (gentamicin and tob-
ramycin) resistance was co-transferred in the same plasmid.
PCR and sequencing analysis of transconjugated plasmids
showed that TEM-1 co-transferred with the CTX-M-15 gene
in all of the isolates, independently of the PFGE type.
DNA plasmid analysis showed that transconjugants
derived from clinical isolates with the same PFGE type
harboured the same plasmid. However, they differed from
transconjugants derived from isolates with different PFGE
types. The size of the plasmids determined by the analysis of
the EcoRI and BamHI restriction enzymes were estimated to
range between 50 kb and 100 kb for all PFGE types.
Interestingly, three isolates of PFGE type A were resistant
to cefoxitin (MIC 128 mg/L). In order to investigate whether
cefoxitin resistance was caused by alterations of the outer
membrane permeability, we analysed the OMPs of suscepti-
ble and resistant K. pneumoniae clinical isolates of PFGE
type A. SDS-PAGE analysis of the OMP of K. pneumoniae
showed only two major proteins, of about 33 kDa and
36 kDa, in the 31–45-kDa range for the cefoxitin-susceptible
isolate (Fig. 2a, lane 1), corresponding to OmpA and
OmpK36, respectively. On the other hand, the expression of
the 36-kDa protein was reduced or absent in two cefoxitin-


























FIG. 1. Dendrogram obtained following pulsed-ﬁeld gel electropho-
resis (PFGE) of XbaI-digested genomic DNA from representative
ESBL-producing Klebsiella pneumoniae PFGE types. Capital letters
below the lanes refer to PFGE types, and numbers above the lanes
refer to the number of isolates of each type. Molecular size markers
(in kb) are indicated on the left.
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resistant isolates (Fig. 2a, lanes 2 and 3, respectively). Inter-
estingly, both OmpK36-deﬁcient strains were also resistant
to ertapenem. By contrast, one of the cefoxitin-resistant iso-
lates did not present alterations in the expression of
OmpK36 (Fig. 2a, lane 4). The porin nature of the 36-kDa
protein present in the cefoxitin-susceptible isolates and
absent or showing reduced expression in two of the resis-
tant isolates was conﬁrmed by western blot analysis, using
speciﬁc antibodies (Fig. 2b).
Discussion
The dissemination of ESBL-producing K. pneumoniae in the
hospital setting is a major threat with important therapeutic
and epidemiological consequences, particularly when it affects
wards caring for critically ill patients. Nowadays, CTX-M-2,
CTX-M-3, CTX-M-14 and CTX-M.15 are the most wide-
spread CTX-M enzymes in different European countries [4].
However, data on ESBL epidemiology in Bosnia-Herzegovina
are scarce.
In this article, we document for the ﬁrst time the pres-
ence of CTX-M-15 in one of the most important hospitals of
this country. We show evidence that most of the CTX-M-
15-producing isolates belonged to two predominant clones,
indicating that, at least in part, dissemination of CTX-M-15
through different wards of the hospital was due to the
spread of these clones. Nevertheless, we also demonstrate
that, in both clones, CTX-M-15 genes were found to be
encoded on large transferable plasmids that might contribute
to the endemic situation that is facing this hospital. Further-
more, TEM-1 and the aminoglycoside resistance genes were
co-transferred with CTX-M-15. This phenomenon has been
previously reported; molecular characterization of plasmids
encoding CTX-M-15 from E. coli strains involved in out-
breaks in different countries have demonstrated that they
additionally carried other antibiotic resistance genes, such as
blaOXA-1, blaTEM-1, tetA, aac(6¢)-Ib-cr, and aac(3)-II [13–15].
Given that b-lactamases degrading cefoxitin are uncom-
mon, cefoxitin is frequently an alternative therapeutic option
for the treatment of hospital-acquired severe infections
caused by multiresistant ESBL-producing K. pneumoniae
strains, such as those described in this work. Nevertheless,
universal susceptibility to this antimicrobial agent in K. pneu-
moniae is no longer guaranteed. Indeed, cefoxitin resistance
development in strains producing ESBLs due to the selection
of mutants with reduced permeability to these antimicrobials
is being increasingly reported [16]. Previous work has shown
that the expression of both major K. pneumoniae porins,
OmpK35 and OmpK36, plays a role in the susceptibility to
TABLE 1. MICs of several b-lactam and non-b-lactam antibiotics for the extended-spectrum b-lactamase (ESBL)-producing
Klebsiella pneumoniae isolates and the Escherichia coli transconjugants harbouring the ESBL-encoding plasmids
Antibiotic
MIC (mg/L) for:
K. pneumoniae isolates from patients of PFGE typea:
E. coli Hb101
E. coli Hb101 transconjugants
harbouring plasmid from PFGE types:
A B C D A B C D
Amoxycillin–clavulanate 8 to >32 16 to >32 16 to >32 >32 <2 4 4 8 4
Piperacillin–tazobactam 32 to >128 <4–64 <4–64 <4–64 <4 <4 <4 <4 <4
Cefoxitin <4–128 <4–8 <4–16 <4 <4 <4 <4 <4 <4
Ceftazidime 16 to >64 >64 16–64 16 to >64 <1 16 4 4 4
Cefotaxime >64 >64 >64 >64 <1 >64 >64 >64 >64
Cefepime 2 to >64 8 to >64 >64 <1–32 <1 <1 <1 <1 <1
Imipenem 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25
Ciproﬂoxacin >4 >4 >4 >4 <0.25 <0.25 <0.25 <0.25 <0.25
Gentamicin >16 8 to >16 >16 >16 <1 >16 8 8 8
Tobramycin 8 to >16 >16 >16 >16 <1 8 8 8 >16
PFGE, pulsed-ﬁeld gel electrophoresis.
aRange of MICs for all ESBL-producing isolates, each recovered from different patients.
OmpK36





FIG. 2. SDS-PAGE (a) and western blotting with anti-OmpK36
serum (b) of outer membrane proteins (OMPs) from the cefoxitin-
susceptible Klebsiella pneumoniae clinical isolate (lane 1), and their
respective in vivo-selected cefoxitin-resistant mutants (lanes 2, 3 and
4). The bands corresponding to OmpK36 and OmpA are indicated
by arrows on the left of both panels. Only the relevant parts of the
gel and western blot are shown.
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cefoxitin antibiotics, and that mutants lacking or having
reduced expression of both OMPs show reduced susceptibil-
ity to this antimicrobial agent. Nevertheless, in this work, we
document and characterize, for the ﬁrst time, development
of in vivo resistance to cefoxitin in CTX-M-15-producing
K. pneumoniae due to the selection of mutations leading to
the lack of porin expression. As frequently occurs in clinical
ESBL-producing K. pneumoniae isolates [12], the epidemic
strains described in this work did not express OmpK35,
favouring cefoxitin resistance development through the inac-
tivation of OmpK36. Overall, CTX-M-15-producing K. pneu-
moniae isolates from three of the 36 adult patients infected
with the prevalent clone type A (8.3%) developed cefoxitin
resistance in clinical samples. Two of them were deﬁcient in
the expression of OmpK36, but one did not shown altered
expression of this porin, suggesting that another resistance
mechanism is involved in the observed phenotype. Given that
the disk-based inhibitor phenotypic assay using boronic acid
or cloxacillin excluded the presence of an AmpC-type
enzyme (data not shown), we hypothesized that cefoxitin
resistance may be caused by mutations in the pore structure
[17] or expression of an efﬂux pump [18].
In summary, we have described for the ﬁrst time the
emergence of CTX-M-15-producing K. pneumoniae isolates in
Bosnia-Herzegovina, and have characterized the mechanisms
leading to in vivo cefoxitin resistance development due to
porin expression deﬁciency in two of the CTX-M-15-
producing K. pneumoniae epidemic strains.
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